{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000088","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.637293+00:00","generated_at":"2026-05-17T14:54:24.900746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mineralys Therapeutics Q2 net loss $43.3M; cash $324.9M; pre-NDA meeting set for Q4 2025","bullets":["Net loss $43.3M vs $41.0M in Q2 2024; R&D expenses $38.3M, G&A $8.5M.","Cash, equivalents and investments $324.9M, sufficient to fund operations into 2027.","Explore-CKD Phase 2 met primary endpoints: 9.25 mmHg systolic BP reduction, 30.51% UACR reduction.","Pre-NDA meeting with FDA scheduled for Q4 2025; Explore-OSA top-line data expected in 1H 2026.","Pivotal Launch-HTN and Advance-HTN results published in JAMA and NEJM."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000088","json":"https://secwatch.observer/filing/0001933414-25-000088.json","markdown":"https://secwatch.observer/filing/0001933414-25-000088.md","text":"https://secwatch.observer/filing/0001933414-25-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/0001933414-25-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/mlys-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:54:24.900746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}